← Human Trials & Peer-Reviewed Studies

Effects of mixing glargine and short-acting insulin analogs on glucose control

Plain-language guide to PMID 15505016 (2004): crossover randomized controlled trial study of Insulin Glargine.

Key Facts

PMID
15505016
Journal
Diabetes care
Year
2004
Study type
Randomized Controlled Trial
Authors
Kaplan W et al. (5 authors)
DOI
10.2337/diacare.27.11.2739
Registered trial
NCT00206401

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at Insulin Glargine.

PubMed holds no abstract for it, so this summary is built from its title ("Effects of mixing glargine and short-acting insulin analogs on glucose control") and its index terms.

Who Took Part

PubMed indexes the participants as teenagers, both men and women.

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the participants took both Insulin Glargine and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Injections, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Glargine.

The publication is from 2004 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page, all human trials.

Our Notes on the Compound

Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.